TEAD4

Artificial Intelligence System Predicts Consequences of Gene Modifications

Retrieved on: 
Wednesday, May 31, 2023

SAN FRANCISCO, May 31, 2023 /PRNewswire/ -- Researchers at Gladstone Institutes, the Broad Institute of MIT and Harvard, and Dana-Farber Cancer Institute have turned to artificial intelligence (AI) to help them understand how large networks of interconnected human genes control the function of cells, and how disruptions in those networks cause disease.

Key Points: 
  • Theodoris and her team used Geneformer to shed light on how heart cells go awry in heart disease.
  • "This approach will greatly advance our ability to design network-correcting therapies in diseases where progress has been obstructed by limited data."
  • Some of those genes, in turn, impact other genes—or loop back and put the brakes on the first gene.
  • However, other potentially important genes identified by Geneformer had not been previously associated with heart disease, such as the gene TEAD4.

Sporos BioDiscovery Presents Preclinical Data on Next-Generation TEAD Inhibitor, SPR1-0117, at the American Association for Cancer Research (AACR) Annual Meeting 2023

Retrieved on: 
Monday, April 17, 2023

“Sporos” or the “Company”), a precision oncology company developing a diversified pipeline of small molecule therapeutic candidates, presented preclinical data for its lead candidate, SPR1-0117, a next-generation TEAD inhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

Key Points: 
  • “Sporos” or the “Company”), a precision oncology company developing a diversified pipeline of small molecule therapeutic candidates, presented preclinical data for its lead candidate, SPR1-0117, a next-generation TEAD inhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
  • SPR1-0117 targets cancers driven by mutations in the Hippo pathway, a key regulator of cell proliferation and oncogenesis not yet extensively targeted in precision oncology.
  • The YAP1/TAZ co-activators and the TEAD family of transcription factors, which consists of four paralogs (TEAD1-4), execute the pro-cancerous effects of the Hippo pathway through transcription of pro-proliferative and anti-apoptotic genes.
  • The published poster is now available in the News & Events section of the Sporos Bioventures website.